Skip to main content

Week In Review: Three New/Expanded Collaborations In Holiday-Shortened Week

This week, Fosun Pharma’s Wanbang subsidiary added animal rights to its development agreement with Vancouver’s Sirona Biochem for a SGLT2 diabetes 2 therapy. As well, Nanjing Triastek was cleared to start US trials of T21 for ulcerative colitis.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.